BioSpace News Archive

Tris Pharma, Inc. (“Tris”) and Athena Bioscience LLC (“Athena”) announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using Tris’ proprietary technology.

Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its fourth quarter 2020 financial results before markets open on Monday, March 8, 2021

Protech Home Medical Corp. (the “Company”) (TSXV:PTQ; OTCQX:PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, today announced that it will host its Q1 Fiscal 2021 earnings conference call and audio webcast on Tuesday, March 2, 2021 at 10:00 a.m. (EST).

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its fourth quarter and year end 2020 financial results and corporate update for Thursday, March 4, 2021.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will participate in the following investor conferences in March

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of its 3D-printed WaveForm TA (TLIF Articulating) Interbody Implant System

Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for a new patent application (number 201680029277.4) covering Allocetra TM ,

ITCI submits Supplemental New Drug Applications (sNDAs) for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults. If approved, CAPLYTA has the potential to treat the broadest range of patients with bipolar depression.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the following upcoming investor conferences: Event: SVB Leerink 10 TH Annual Global Healthcare Conference 2021 (Virtual) Date: Wednesday, February 24 TH Presentation Time: 1:00 p.m. EST

Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. ET.